Precision BioSciences, Inc. announced new data from its ongoing ELIMINATE-B Phase 1 study evaluating PBGENE-HBV, a first-in-class in vivo gene editing therapy for chronic Hepatitis B. The results were presented as a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® on November 10, 2025. The data included results from nine patients across 22 doses in the first three cohorts, showing that PBGENE-HBV was well-tolerated at doses up to 0.8 mg/kg with no dose-limiting toxicities and demonstrated cumulative, dose-dependent antiviral activity. Precision BioSciences plans to advance PBGENE-HBV into the Part 2 expansion phase of the trial to further evaluate safety and efficacy in a larger patient population.